QIBA PET Amyloid Biomarker Committee
17 July 2015 at 9:00 AM CT (GMT-6)
Call Summary

In attendance:

**Participants:**
- John Hoffman, MD
- Nancy Obuchowski, PhD
- Joe Koudelik
- Satoshi Minoshima, MD, PhD
- Abhinay Joshi, MS
- Rathan Subramaniam, MD, PhD, MPH
- Susan Weinmann
- Eric Perlman, MD
- Paul Kinahan, PhD, FIEEE
- John Sunderland, PhD
- Abhinay Joshi, MS
- Richard Wahl, MD, FACP
- Anne Smith, PhD
- Adriaan Lammertsma, PhD
- Brian Zimmerman, PhD

**Administrative Update**

- The changes in QIBA leadership were noted
  - QIBA Chair: Dr. Sullivan has stepped down and Dr. Jackson has filled this position
  - QIBA Vice-Chair: Dr. Perlman has succeeded Dr. Jackson

- NIBIB YR 4 project final reports due to RSNA by August 31 (no project extensions are possible)
  - PET Amyloid brain physical phantom (Dr Sunderland)
    - Gathering data and manual adjustment of 100s of phantom image sections ongoing
    - Drs Sunderland and Kinahan to discuss data-requirements offline
  - PET Amyloid brain DRO / phantom (Dr Kinahan)
    - DRO project on schedule and expected to complete by Aug 31
  - FDG-PET/CT Profile Feasibility Test - Part 2 (Dr Turkington)

- NIBIB YR 5 RFP
  - RSNA submitted a proposal on July 14
  - Funding decision expected late Aug/ early Sept 2015
  - Projects using contract funds for human subject imaging have been removed due to caveat in RFP language

- Project proposal scoring status
  - Generally, all NM proposals received favorable rankings by the QIBA Steering Cmte
  - Outcome pending NIBIB decision & available funding level

**Profile Revision Work**

- Claim language (Section 2)
  - Use partial literature dataset for initial performance estimates
  - Revise based on meta-analysis when available
  - Review ‘dependencies / disclaimers’
  - Define performance requirement (e.g., repeatability coefficient or within subject standard deviation)
  - Consider different level of performance characteristics dependent upon absolute level of amyloid burden at baseline. To be investigated at time of literature review.
  - Define percent change as \(\frac{\text{SUVR@time2} - \text{SUVR@time1}}{\text{SUVR@time1}} \times 100 = \%\text{chg SUVR}\)

- Threshold(s) for tracer uptake time differential – to be discussed at future meeting

- BC members requested to review Profile draft of 16June2015 and submit suggested revisions, deletions, additions using the spreadsheet format previously provided to co-chairs and/or RSNA staff for compilation and future session review.
Upcoming Nuclear Medicine Calls (Fridays, 9 am CT):

- **July 24:** All NM BC Co-Chairs Call – note: in place of SPECT BC
- **July 31:** SPECT Biomarker Ctte Call – note: switch from July 24
- **August 7:** FDG-PET Biomarker Ctte Call
- **August 14:** Amyloid Biomarker Ctte Call
- **August 21:** SPECT Biomarker Ctte Call
- **August 28:** Combined NM Biomarker Committees